retatrutide study news today Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Promises Big Weight Loss,

This process ensures appropriate patient selection, safety screening, and ongoing medical supervision throughout treatment

For a deeper look at the digestive side of treatment, read our overview of common GLP-1 side effects

There were no ICP lowering agents or addition of headache preventative drugs started during the study

Cholelithiasis is a common complication associated with weight reduction interventions, with the incidence of new gallstone formation exceeding 30% after gastric bypass surgery in obese populations [40]

For researchers who use semaglutide alongside or as an alternative to tirzepatide, separate calculators handle the semaglutide reconstitution math since the dosing ranges are different